Migraine is a leading cause of disability worldwide. Approximately 15% of 
Americans experience migraines. Most people who have migraines feel that people 
who do not have them often underestimate their condition. Migraines affect 
people's quality of life and ability to participate in work, family, and social 
events. A new class of medication, calcitonin gene-related peptide (CGRP) 
antagonists, has been approved for migraine prevention in adults. The newly 
approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while 
eptinezumab looks to 2020 for approval. Lasmiditan, ubrogepant, and rimegepant 
are currently emerging acute migraine therapies that may be added to the arsenal 
of current migraine management.